1:26-cv-00272
Novartis Pharma Corp v. Cipla USA Inc
I. Executive Summary and Procedural Information
- Parties & Counsel:
- Plaintiff: Alnylam Pharmaceuticals, Inc. (Delaware); The Medicines Company (Delaware); Novartis Technology LLC (Delaware); Novartis Pharmaceuticals Corporation (Delaware)
- Defendant: Cipla USA Inc. (Delaware); Cipla Ltd. (Republic of India)
- Plaintiff's Counsel: McCarter & English, LLP; Williams & Connolly LLP
- Case Identification: 1:26-cv-00272, D. Del., 03/13/2026
- Venue Allegations: Venue is asserted in the District of Delaware because Defendant Cipla USA Inc. is a Delaware corporation, and Cipla Ltd. has allegedly purposefully availed itself of the jurisdiction.
- Core Dispute: Plaintiffs allege that Defendants' submission of an Abbreviated New Drug Application (ANDA) for a generic version of the cholesterol-lowering drug LEQVIO® (inclisiran) constitutes an act of infringement of three U.S. patents.
- Technical Context: The technology involves RNA interference (RNAi), a gene-silencing mechanism, using double-stranded RNA agents (siRNA) to inhibit the production of the PCSK9 protein, a key regulator of cholesterol levels.
- Key Procedural History: This action was precipitated by Defendants' notification letter, dated January 28, 2026, informing Plaintiffs of their ANDA submission to the FDA. This ANDA included a Paragraph IV certification, asserting that the patents-in-suit are invalid, unenforceable, or will not be infringed by the proposed generic product. The patents-in-suit are listed in the FDA's "Orange Book" as covering LEQVIO®.
Case Timeline
| Date | Event |
|---|---|
| 2012-12-05 | Earliest Priority Date for '369, '377, and '206 Patents |
| 2018-11-13 | '369 Patent Issued |
| 2020-12-01 | '377 Patent Issued |
| 2025-11-04 | '206 Patent Issued |
| 2026-01-28 | Cipla's Notice Letter Sent |
| 2026-03-13 | Complaint Filed |
II. Technology and Patent(s)-in-Suit Analysis
U.S. Patent No. 10,125,369 - "PCSK9 iRNA Compositions and Methods of Use Thereof"
- Issued: November 13, 2018
The Invention Explained
- Problem Addressed: The patent addresses the need for effective treatments for PCSK9-associated diseases, such as hypercholesterolemia (high cholesterol), which are significant risk factors for cardiovascular disease (('369 Patent, col. 1:21-2:25)). The PCSK9 protein reduces the liver's ability to clear "bad" cholesterol (LDL-C) from the blood.
- The Patented Solution: The invention provides a double-stranded RNAi agent designed to inhibit the expression of the PCSK9 gene, thereby reducing PCSK9 protein levels and allowing more LDL-C to be removed from the bloodstream (('369 Patent, abstract)). To improve delivery of the RNAi agent to liver cells, the agent is conjugated to a specific ligand, N-acetylgalactosamine (GalNAc), which binds to receptors on liver cells (('369 Patent, col. 31:58-67)).
- Technical Importance: The use of a GalNAc-conjugated RNAi agent represented a significant advance in targeting gene-silencing therapeutics to the liver with improved stability and potency.
Key Claims at a Glance
- The complaint specifically identifies claim 52, which depends from independent claim 1, as an example of an infringed claim Compl. ¶36
- The essential elements of independent claim 1 are:
- A double stranded RNAi agent that inhibits the expression of Proprotein convertase subtilisin kexin 9 (PCSK9) in a cell,
- wherein the double stranded RNAi agent comprises a sense strand and an antisense strand forming a double stranded region,
- wherein the sense strand is complementary to the antisense strand,
- wherein the sense strand comprises a region that is complementary to part of an mRNA encoding PCSK9,
- wherein each strand is about 14 to about 30 nucleotides in length,
- wherein the double stranded RNAi agent is represented by formula (III).
- The complaint reserves the right to assert other claims, including claims 1-52, 54-63, and 65-85 Compl. ¶39
U.S. Patent No. 10,851,377 - "Methods and Compositions for Treating a Proprotein Convertase Subtilisin Kexin (PCSK9) Gene-Associated Disorder"
- Issued: December 1, 2020
The Invention Explained
- Problem Addressed: While RNAi agents for PCSK9 were known, there was a need to define specific, effective, and durable clinical dosing regimens for human patients to treat PCSK9-related disorders like hypercholesterolemia (('377 Patent, col. 2:19-23)).
- The Patented Solution: This patent claims a method of treatment using the RNAi agent inclisiran. The invention specifies a method comprising the subcutaneous administration of a "fixed dose of 275 mg to 325 mg" of a specific double-stranded RNAi agent, which has defined nucleotide sequences and chemical modifications (('377 Patent, abstract; '377 Patent, col. 2:24-41)). The patent also describes dosing schedules involving loading and maintenance phases (('377 Patent, col. 4:1-12)).
- Technical Importance: This patent moves from the composition of the drug to its clinical use, providing a specific, patented method for administering the therapeutic to achieve a desired effect on PCSK9 levels.
Key Claims at a Glance
- The complaint asserts independent claim 1 Compl. ¶59
- The essential elements of independent claim 1 are:
- A method of inhibiting the expression of a PCSK9 gene in a human subject,
- comprising subcutaneously administering to the subject a fixed dose of 275 mg to 325 mg of a double stranded RNAi agent, or salt thereof,
- wherein the agent consists of a sense strand with the nucleotide sequence of SEQ ID NO: 687 and an antisense strand with the nucleotide sequence of SEQ ID NO: 688,
- wherein the agent includes specified chemical modifications (2'-O-methyl, 2'-fluoro) and phosphorothioate linkages,
- and wherein the agent is conjugated to a N-acetylgalactosamine (GalNAc)3 ligand.
- The complaint reserves the right to assert other claims Compl. ¶59
U.S. Patent No. 12,460,206 - "PCSK9 iRNA Compositions and Methods of Use Thereof"
- Issued: November 4, 2025 Compl. ¶76
Technology Synopsis
This patent claims a pharmaceutical composition comprising a specific double-stranded RNAi agent that inhibits PCSK9 expression. The agent is defined by its exact sense and antisense nucleotide sequences (inclisiran) and its conjugation to a ligand shown in a specific schematic (('206 Patent, abstract; '206 Patent, claim 1)). This composition is formulated in a sterile aqueous solution (('206 Patent, claim 2)).
Asserted Claims
The complaint asserts independent claim 1 Compl. ¶83
Accused Features
The complaint alleges that Cipla's ANDA Product is a pharmaceutical composition that contains inclisiran, the specific RNAi agent claimed, in a sterile aqueous solution Compl. ¶¶84-85
III. The Accused Instrumentality
Product Identification
The accused instrumentality is Defendants' proposed generic version of LEQVIO® (inclisiran) injection, 284 mg/1.5 mL, which is the subject of ANDA No. 220297 submitted to the FDA Compl. ¶1 Compl. ¶26
Functionality and Market Context
The complaint alleges that the accused product is a small interfering RNA (siRNA) therapeutic designed to lower low-density lipoprotein cholesterol (LDL-C) by inhibiting the expression of the PCSK9 gene Compl. ¶25 It is alleged to contain the active ingredient inclisiran, which is a double-stranded RNAi agent comprising specific sense and antisense nucleotide sequences Compl. ¶37 Compl. ¶38 The complaint includes a schematic that illustrates the chemical structure of the ligand allegedly conjugated to the inclisiran molecule Compl. p. 17 This product is a generic version of a branded pharmaceutical, LEQVIO®, intended for patients with hypercholesterolemia Compl. ¶25 Compl. ¶26
IV. Analysis of Infringement Allegations
'369 Patent Infringement Allegations
The complaint does not provide sufficient detail for a full claim chart analysis against the specific language of Formula (III) in Claim 1. However, the narrative infringement theory for key aspects of Claim 1 is summarized below.
| Claim Element (from Independent Claim 1) | Alleged Infringing Functionality | Complaint Citation | Patent Citation |
|---|---|---|---|
| A double stranded RNAi agent that inhibits the expression of Proprotein convertase subtilisin kexin 9 (PCSK9) in a cell... | Cipla's ANDA Product contains inclisiran, which is a double stranded RNAi agent that inhibits the expression of PCSK9 in a cell. | ¶37 | col. 1:19-20 |
| ...wherein the double stranded RNAi agent comprises a sense strand and an antisense strand... | Inclisiran comprises a sense strand and an antisense strand. | ¶38 | col. 14:32-35 |
| ...wherein each strand is about 14 to about 30 nucleotides in length... | The alleged sense and antisense strands of inclisiran fall within the claimed length. | ¶38 | col. 752:4-5 |
| ...wherein the double stranded RNAi agent is represented by formula (III): [Formula containing a ligand] | The inclisiran in Cipla's ANDA product is allegedly conjugated to a ligand as shown in the schematic in the complaint, which corresponds to the structure of Formula (III). | ¶38; ¶85 | col. 3:42-4:10 |
'377 Patent Infringement Allegations
| Claim Element (from Independent Claim 1) | Alleged Infringing Functionality | Complaint Citation | Patent Citation |
|---|---|---|---|
| A method of inhibiting the expression of a Proprotein convertase subtilisin kexin 9 (PCSK9) gene in a human subject, comprising subcutaneously administering to the subject a fixed dose of 275 mg to 325 mg of a double stranded ribonucleic acid (RNAi) agent, or salt thereof... | Cipla's ANDA seeks approval for a product with a dose of 284 mg, which is within the claimed range. The proposed label will instruct for subcutaneous administration. | ¶59; ¶60; ¶61 | col. 411:60-65 |
| ...wherein the double stranded RNAi agent consists of the nucleotide sequence of the sense strand of 5'-csusagacCfuuGfuuTungcuuuuguu-3' (SEQ ID NO: 687) and the antisense strand consists of the nucleotide sequence of 5'-asCfsAafAfgGcfuAafAfgGfuCfuuagaasa-3' (SEQ ID NO: 688)... | The complaint alleges, based on Cipla's Notice Letter, that the inclisiran in the ANDA product has the exact sense and antisense sequences recited in the claim. | ¶62 | col. 412:1-13 |
| ...wherein the double stranded RNAi agent is conjugated to a N-acetylgalactosamine (GalNAc)3 ligand... | The complaint alleges, based on Cipla's Notice Letter, that the inclisiran in the ANDA product is conjugated to a GalNAc3 ligand. | ¶62 | col. 412:14-16 |
| ...wherein a, c, g, and u are 2'-O-methyl (2'-OMe) A, G, C, and U; Af, Gf, Cf, and Uf are 2'-fluoro A, G, C, and U; s is a phosphorothioate linkage... | The complaint alleges that the inclisiran in the ANDA product contains the specified chemical modifications. | ¶62 | col. 412:13-17 |
Identified Points of Contention
- Validity vs. Infringement: The complaint alleges that for certain claims of the '369, '377, and '206 patents, Cipla's Notice Letter did not contest infringement on any basis other than alleged invalidity Compl. ¶39 Compl. ¶63 Compl. ¶86 This suggests that the central dispute for these claims may be over patent validity (e.g., obviousness, lack of enablement/written description) rather than a factual dispute over whether Cipla's product meets the claim limitations.
- Scope Questions: While the complaint alleges a direct structural match, a potential point of contention in litigation could be the scope of the term "double stranded RNAi agent" and whether the specific combination of sequence, length, chemical modifications, and ligand conjugation was obvious over the prior art at the time of the invention.
V. Key Claim Terms for Construction
The Term: "inhibiting the expression"
- Patents: '369 Patent, claim 1; '377 Patent, claim 1
Context and Importance
This term is central to the function of the claimed invention. The degree or threshold of inhibition required to meet this limitation could become a point of contention. The parties may dispute whether any level of reduction suffices, or if a specific, therapeutically meaningful level of reduction is required by the claims.
Intrinsic Evidence for Interpretation
- Evidence for a Broader Interpretation: The specification provides a wide range of possible inhibition levels, stating "inhibition of expression of a PCSK9 gene" can be "at least about 5%, at least about 10%...at least about 95%, or at least about 98%" (('369 Patent, col. 17:7-12)). This language may support an interpretation that any statistically significant reduction meets the limitation.
- Evidence for a Narrower Interpretation: Defendants may point to specific examples or efficacy data in the patent (e.g., Figures 1, 2A, 2B) to argue that the term implies a level of inhibition that is therapeutically effective, potentially importing a higher threshold than "any" inhibition (('369 Patent, Figs. 1-2B)).
The Term: "a double stranded RNAi agent ... represented by formula (III)"
- Patent: '369 Patent, claim 1
Context and Importance
This term defines the core chemical structure of the '369 patent's composition claim. Formula (III) depicts a double-stranded agent with a ligand attached. The precise structural features encompassed by this formula, and how it relates to the accused product, will be critical for infringement.
Intrinsic Evidence for Interpretation
- Evidence for a Broader Interpretation: The specification describes a wide variety of possible ligands and linkers that can be used, suggesting "formula (III)" should be interpreted as representative rather than strictly limiting (('369 Patent, col. 31:58-34:21)).
- Evidence for a Narrower Interpretation: The specific chemical structure depicted in Formula (III) itself, and the corresponding detailed schematic for the GalNAc ligand, could be argued to limit the claim to that particular arrangement or a very narrow range of equivalents (('369 Patent, col. 3:42-4:10; '369 Patent, col. 32:29-33:14)).
VI. Other Allegations
Indirect Infringement
Plaintiffs allege active inducement of infringement for all three patents, particularly the '377 method patent Compl. ¶41 Compl. ¶65 Compl. ¶88 The factual basis is the allegation that Cipla's proposed product labeling for its ANDA product will "instruct, or otherwise encourage, recommend, or promote" healthcare providers and patients to use the product in a manner that directly infringes the patented methods of administration Compl. ¶60
Willful Infringement
The complaint does not use the term "willful," but it lays a foundation for such a claim. It alleges that Cipla had pre-suit knowledge of the Patents-in-Suit through their listing in the FDA's Orange Book and by receiving the Notice Letter Compl. ¶32 Compl. ¶33 The complaint further alleges that Cipla "knowingly and deliberately challenged" the patents, which could be used to support an argument that any infringement, if found, was willful Compl. ¶18
VII. Analyst's Conclusion: Key Questions for the Case
- A core issue will be one of patent validity. The complaint suggests that Defendants are not disputing that their product's composition and proposed method of use match the claims, but are instead arguing that the patents themselves are invalid. The central question for the court will likely be whether Defendants can meet their burden of proving, by clear and convincing evidence, that the asserted claims are invalid over the prior art or for failure to meet statutory requirements like written description and enablement.
- A second key question concerns induced infringement, particularly for the '377 method patent. The analysis will focus on whether the language in Cipla's proposed product labeling provides sufficient evidence of an affirmative act and specific intent to encourage or instruct others to perform the patented method of administering a specific dose of inclisiran.
- A final question relates to claim scope and equivalence. While the complaint pleads direct identity between the accused product and the claimed inventions, the case may evolve to scrutinize the precise meaning of terms like "ligand" and the specific nucleotide sequences, raising questions of whether minor variations fall outside the literal scope of the claims and whether they would be considered equivalent under the doctrine of equivalents.